

# Pharmacological Targeting of Neutrophil Serine Proteases Prevents Lethality in Dextran Sulfate Sodium (DSS)-Induced Colitis in Mice

Hisashi Ro, Shinya Munakata\*, Takae Ueyama, Hiromitsu Komiyama, Makoto Takahashi, Yutaka Kojima, Yuichi Tomiki and Kazuhiro Sakamoto

Department of Coloproctological Surgery, Juntendo University, Faculty of Medicine, Tokyo, Japan

\*Corresponding author: Munakata S, Department of Coloproctological Surgery, Juntendo University, Faculty of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan, Tel: +81-3-3813-3111; E-mail: [smunaka@juntendo.ac.jp](mailto:smunaka@juntendo.ac.jp)

Received date: January 17, 2018; Accepted date: February 02, 2018; Published date: February 08, 2018

Copyright: © 2018 Ro H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## Abstract

**Background and aims:** In recent years the number of patients with inflammatory bowel diseases such as Crohn's disease and ulcerative colitis has been on the rise. Neutrophils are thought to be first cells to colonize disease-state colon tissue. Neutrophil elastase (NE) and cathepsin-G (Cat-G) are major secretory products from activated neutrophils and a major contributor to tissue destruction in inflammatory diseases. We predicted that inhibiting neutrophils and their proteases would improve ulcerative colitis.

**Methods:** Acute colitis was induced in mice by oral administration of 2% DSS for 7 days. In the first experiment, an inhibitor of Gr-1, a key neutrophil protein, was administered. In the second, the respective antagonists for NE and Cat-G, proteinases secreted by neutrophils, were administered, and the conditions of DSS-induced colitis were evaluated for improvement. Blood samples were collected and analyzed for levels of cytokines.

**Results:** The survival rate and pathology were improved in the Gr-1 inhibition experiments. In addition, administration of inhibitors of NE and Cat-G also resulted in clinical improvement. However, elevation of TNF- $\alpha$ , a key cytokine, was not suppressed in either experiment.

**Conclusion:** The proteolytic environment of neutrophils is associated with colonic inflammation. Disruption of the neutrophil proteases NE and Cat-G might therefore be a strategy for treatment of colitis regardless of TNF-suppression.

**Keywords:** Colitis; Neutrophil; Proteases

**Abbreviations:** Ab: Antibody; DSS: Dextran Sulfate Sodium; CD: Crohn's Disease; UC: Ulcerative Colitis; FACS: Fluorescence-activated cell sorting

Received: January 17, 2018; Accepted: February 02, 2018; Published: February 08, 2018

© 2018






Figure 1:



**Figure 2** ONO-5046 suppresses the development of murine DSS-

the pathogenesis of acute lung injury, hypercytokinemia can develop in which neutrophils are activated to accumulate in the lungs and release NE. DSS injures pulmonary vascular endothelial cells and alveolar epithelial cells, causing increased pulmonary vascular permeability. ONO-5046 improves acute lung injury by selectively inhibiting NE [15]. Moreover, we found that ONO-5046 overcame the role of MMP9, but NE was not present on the upstream protease of MMP9 (data not shown). However, as Morohoshi et al. have shown, ONO-5046 might actually have the potential to be a new therapeutic approach for patients with active UC [5].

On the other hand, Cat-G also induced the conversion of proMMP-1 to active MMP-1 in photoaging in hairless mice [16]. Another Cat-G inhibitor was shown to reduce neutrophil infiltration into sites of inflammation and counteract asthma pathophysiology [17]. We likewise demonstrated that a Cat-G inhibitor ameliorated the DSS-induced inflammation. In addition, NE- and MMP9-deficient mice showed a decreased response in a rheumatoid arthritis model. This defect was accompanied by a decrease in local production of TNF- $\alpha$  and IL-1 [18]. It is generally accepted that the TNF- $\alpha$ /TNF- $\beta$  ratio is regulated mainly through shedding of cytokines from the cell surface by activated ADAM17. Other proteases present at the cell surface, such as Cat-G and NE, may also contribute to TNF- $\alpha$  shedding [19]. The TNF- $\alpha$  of our colitis model could not be regulated by inhibition of Cat-G and NE. This phenomenon is considered to depend on the particular disease.

In actual clinical trials, while mild cases of IBD may respond to aminosalicylates for induction and maintenance of remission, for management of severe IBD the current situation is far from satisfactory, especially in cases of steroid-dependent or steroid-refractory IBD, or in patients who are intolerant to corticosteroids. The widespread use of anti-TNF- $\alpha$  agents has changed the treatment paradigm in the management of patients with IBD [20]. These therapies are associated with a higher rate of induction of remission, but agents usually reserved for more severe disease have been known to fail in approximately 40% of patients [9,10]. A new target therapy is required such as anti-integrin therapy or inhibition of inflammatory cytokines such as IL-13, IL-17, and IL-23/24 [9,21,22] in humans but also, for instance, plasmin inhibitor; MMP inhibitor; cannabinoids and palmitoylethanolamide in mice [4,23,24]. In conclusion, our data suggest that serine proteases are activated during colitis progression. This proteolytic environment controls cell infiltration into colonic tissues, but not the production and secretion of the inflammatory cytokine TNF- $\alpha$ . Our results suggest that the targeting of NE and Cat-G is an attractive therapeutic candidate for TNF- $\alpha$  refractory IBD.

Study concept and design, SM; Data acquisition, HR, SM, TU; Analysis and interpretation of data, HR, SM, TU; 8FU [b] of the manuscript, SM; Critical revision of the manuscript, SM, HK, MT, YK, YT, KS.

The authors have no conflicts of interest to declare.

This work was supported in part by grants from the Japan Society for the Promotion of Science (Wakate B grant no. 16K19956 and 15H06603).

The authors thank the Division of Molecular and Biochemical Research, Research Support Center (Juntendo University Graduate School of Medicine) for technical assistance.

1. Baumgart DC, Carding SR (2007) Inflammation and bowel disease: Cause and immunobiology. *Lancet* 369: 1627-1640.
2. Podolsky DK (2002) Inflammation and bowel disease. *N Engl J Med* 347: 417-429.
3. Soehnlein O, Weber C, Lindbom L (2009) Neutrophil granule proteins tune monocyte cell function. *Trends Immunol* 30: 538-546.
4. Munakata S, Tashiro Y, Nishida C, Sato A, Komiyama H, et al. (2014) Inhibition of plasmin protects against colitis in mice by suppressing matrix metalloproteinase 9-mediated cytokine release from myeloid cells. *Gastroenterology* 148: 565-578.
5. Morohoshi Y, Matsuoka K, Chinen H, Kamada N, Sato T, et al. (2006) Inhibition of neutrophil elastase prevents the development of murine dextran sulfate sodium-induced colitis. *J Gastroenterol* 41: 318-324.
6. Ferry G, Lonchampt M, Pennel L, de Nanteuil G, Canet E, et al. (1997) Activation of MMP-9 by neutrophil elastase in an in vivo model of acute lung injury. *FEBS Letters* 402: 111-115.
7. Padrines M, Wolf M, Wälz A, Baggiolini M (1994) Interleukin-8 processing by neutrophil elastase, cathepsin G and proteinase-3. *FEBS Lett* 352: 231-235.
8. Sands BE, Sandborn WJ, Feagan B, et al. (2008) A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. *Gastroenterology* 135: 400-409.
9. Danese S (2012) New therapies for inflammatory bowel disease: From the bench to the bedside. *Gut* 61: 918-932.
10. Järnerot G, Hertvig E, Friis-Liby I, Blomquist L, Karlén P, et al. (2005) Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study. *Gastroenterology* 128: 1805-1811.
11. Cooper HS, Murthy SN, Shah RS, Sedergran DJ (1993) Clinicopathologic study of dextran sulfate sodium experimental murine colitis. *Lab Invest* 69: 238-249.
12. Kuwana T, Sato Y, Saka M, Kondo Y, Miyata M, et al. (2000) Anti-cathepsin G antibodies in the sera of patients with ulcerative colitis. *J Gastroenterol* 35: 682-689.
13. Hall LJ, Faivre E, Quinlan A, Shanahan F, Nally K, et al. (2011) Induction and activation of adaptive immune populations during acute and chronic phases of a murine model of experimental colitis. *Dig Dis Sci* 56: 79-89.
14. Pham CT (2006) Neutrophil serine proteases: Cofactors and regulators of inflammation. *Nat Rev Immunol* 6: 541-550.
15. Polverino E, Rosales-Mayer E, Dale GE, Dembrowsky K, Torres A (2017) The role of neutrophil elastase inhibitors in lung diseases. *Chest* 152: 249-262.
16. Son ED, Shim JH, Choi H, Kim H, Lim KM, et al. (2012) Cathepsin G inhibitor prevents ultraviolet B-induced photoaging in hairless mice via inhibition of collagen fragmentation. *Dermatology* 224: 352-360.
17. Ahrén BE, de Garavilla L, Greco MN, Haertlein BJ, Wells GI, et al. (2010) Dual inhibition of cathepsin G and chymase is a novel animal model of pulmonary inflammation. *Am J Respir Crit Care Med* 181: 247-253.

